Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

EMA Flags Tavneos Trial Breaches; EU Revokes Approval Over Data Integrity

European regulators have revoked Tavneos’ marketing authorization in the EU and EEA after finding serious problems in how data from its pivotal ADVOCATE study were handled. The EMA concluded that the study could no longer reliably demonstrate efficacy after unblinded
  • News
EMA Flags Tavneos Trial Breaches; EU Revokes Approval Over Data Integrity

Phase III Trials Hit 5.9M Data Points; Can Manual Review Protect Trial Integrity?

Clinical trials now collect an average of 5.9 million data points in each Phase III protocol, while many sponsors still depend on manual, periodic reviews. This mismatch can delay the detection of protocol deviations, safety signals, and data inconsistencies. As
  • News
Phase III Trials Hit 5.9M Data Points; Can Manual Review Protect Trial Integrity?

Hippocratic AI Buys Grove AI; Who Validates AI-Led Patient Screening?

Hippocratic AI acquired Grove AI in January 2026 after the startup spent two years building voice agents for clinical trial recruitment. Grove’s technology speaks with patients, collects screening information and helps match them with enrolling studies. The deal shows how
  • News
Hippocratic AI Buys Grove AI; Who Validates AI-Led Patient Screening?